

**TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED**  
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)  
(Company Registration No.: 91120000103100784F)  
(Incorporated in the People's Republic of China)

---

**CLOSURE OF TWO DESIGNATED ACCOUNTS FOR THE PROCEEDS FROM THE PLACEMENT**

---

*The board of directors (the “Board”) and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the “Company”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.*

The Board refers to:

- (a) the previous announcements by the Company on 12 June 2014, 12 August 2014, 7 January 2015, 28 January 2015, 27 March 2015, 28 April 2015, 8 June 2015, 15 July 2015, 22 July 2015, 14 August 2015, 26 August 2015, 1 September 2015, 7 September 2015, 28 September 2015, 9 October 2015, 15 October 2015, 30 October 2015, 10 November 2015, 17 November 2015, 8 December 2015, 11 December 2015, 23 December 2015, 19 January 2016, 8 March 2016 and 21 March 2016, 26 April 2016, 8 June 2016, 5 July 2016, 12 August 2016, 24 August 2016, 26 August 2016, 29 November 2016, 7 March 2017, 30 March 2017, 13 June 2017, 14 August 2017, 23 August 2017, 24 August 2017, 28 November 2017, 8 January 2018, 30 March 2018, 9 August 2018, 14 August 2018, 24 August 2018, 29 March 2019, 14 August 2019, 23 August 2019, 17 April 2020, 14 August 2020, 30 September 2020, 30 March 2021, 13 August 2021, 8 September 2021, 13 September 2021, 30 March 2022, 9 August 2022, 12 August 2022, 31 March 2023, 10 August 2023, 14 August 2023, 29 March 2024, 9 August 2024, 14 August 2024, 28 March 2025 and 29 May 2025 in relation to the Placement (the “**Prior Announcements**”);
- (b) the circular dated 1 August 2014 (the “**Circular**”) in relation to the Placement;
- (c) the circular dated 24 September 2018 in relation to, amongst others, the proposed change in the use of the Net Proceeds raised from the Placement; and
- (d) the annexure dated 30 April 2025 (the “**Annexure**”) to the notice of annual general meeting in relation to the proposed cessation, adjustment of investment scale and termination of the Projects funded by the Proceeds from the Placement and the permanent reallocation of the remaining Proceeds to working capital (the “**Proposed Cessation of Projects and Reallocation of Proceeds**”).

*Unless otherwise defined, all capitalised terms used herein shall bear the same meanings ascribed to them in the Prior Announcements, the Circular and the Annexure.*

**1. INFORMATION ON THE PLACEMENT AND THE PROCEEDS**

Following the written approval from the China Securities Regulatory Commission (中国证券监督管理委员会) received by the Company on 8 June 2015, the Company issued 29,564,356 A-Shares with a par value of RMB1.00 per share at an issue price of RMB28.28 per share on 19 June 2015, and the Proceeds from the Placement amounted to approximately

RMB836,079,987.68. After deducting the expenses relating to the Placement, the Net Proceeds amounted to approximately RMB814,340,000.00.

The Proceeds were deposited into the Designated Accounts on 25 June 2015. Ruihua Certified Public Accountants LLP, on 26 June 2015, issued a proceeds verification report confirming that the Proceeds raised from the Placement were duly deposited into the Designated Accounts (i.e. the Designated Account #1, the Designated Account #2, and the Designated Account #3).

## 2. MANAGEMENT OF THE PROCEEDS

To further regulate the use and management of the Proceeds, improve the efficiency of the utilisation of the Net Proceeds, and protect investors' interests, pursuant to relevant laws, regulations and rules including the *Company Law of the PRC* (《中华人民共和国公司法》), the *Securities Law of the PRC* (《中华人民共和国证券法》), the *Administrative Measures for the Issuance of Securities by Listed Companies* (《上市公司证券发行管理办法》), the listing rules of the Shanghai Stock Exchange (the “SSE”), as well as the Articles of Association of the Company, and taking into account the actual circumstances of the Company, the Company adopted the Measures for the Management of Proceeds (募集资金管理办法), which was approved by Shareholders at the 1<sup>st</sup> extraordinary general meeting of the Company in 2014 held on 18 August 2014.

Further, to ensure proper management of the Proceeds and safeguard investor interests, the tripartite Supervision Agreements (i.e. the Supervision Agreement #1, the Supervision Agreement #2, and the Supervision Agreement #3) were entered into among the Company, Tianjin Da Ren Tang (Bozhou) Chinese Medicine Co., Ltd. (天津达仁堂(亳州)中药饮片有限公司) (“Bozhou Company”), the Placement Agent, and the respective designated banks. The Company has strictly complied with the applicable laws, regulations and rules in depositing, utilising, and managing the Proceeds, and has been providing Shareholders with regular updates via announcements published on the website of the SSE and via SGXNET.

As at the date of this announcement, the status of the Designated Accounts is as follows:

Account Name	Designated Banks	Bank Account Number	Remarks
The Company	China Bohai Bank Co., Ltd., Tianjin Rongye Street Sub-Branch (previously known as China Bohai Bank Co., Ltd., Tianjin Duolun Road Sub-Branch)	2000001695000328 (i.e. the Designated Account #1)	In normal use
The Company	Industrial and Commercial Bank of China, Tianjin Chengdu Road Sub-Branch (“ICBC”)	0302010529300330596 (i.e. the Designated Account #2)	Closed
Bozhou Company	China Construction Bank, Tianjin Hebei Sub-Branch (“CCB”)	12001660800052535320 (i.e. the Designated Account #3)	Closed

## 3. CLOSURE OF TWO DESIGNATED ACCOUNTS

The Proposed Cessation of Projects and Reallocation of Proceeds was approved by the Board and the Supervisory Committee at the Company's 1<sup>st</sup> Board and 1<sup>st</sup> Supervisory Committee

meetings for the financial year ending 31 December 2025 (“**FY2025**”), held on 28 March 2025, respectively, and was approved by Shareholders at the Company’s annual general meeting for the financial year ended 31 December 2024 (the “**2025 AGM**”) held on 15 May 2025. Please refer to Appendix A to the announcement dated 28 March 2025 made by the Company in relation to, *inter alia*, the resolutions passed at the 1<sup>st</sup> Board meeting for FY2025, the announcement dated 15 May 2025 made by the Company in relation to the poll results of the 2025 AGM, and the Annexure for further details of the Proposed Cessation of Projects and Reallocation of Proceeds.

As at the date of this announcement, the Company has transferred the following funds to the bank account(s) designated by the Company:

- (i) the entire unutilised Proceeds from the Designated Accounts corresponding to the Terminal Marketing Network and Promotional System Project, the Bozhou Industrial Park Construction Project (comprising the Chinese Medicine Extraction and Preparation Project and the Project on Chinese Medicine Decoction Pieces);
- (ii) part of the unutilised Proceeds from the Designated Account corresponding to the Phase I Dripping Pill Manufacturing Base Project; and
- (iii) the interest income and returns from financial management generated from the Proceeds.

The Designated Account #2 with ICBC and the Designated Account #3 with CCB have been closed accordingly, following which the tripartite Supervision Agreements relating to the Designated Account #2 and the Designated Account #3, entered into among the Company, the Placement Agent, and the respective designated banks (i.e. ICBC and CCB), have been terminated.

**By order of the Board**

Jiao Yan  
Secretary to the Board of Directors  
13 August 2025